JP2010065037A5 - - Google Patents

Info

Publication number
JP2010065037A5
JP2010065037A5 JP2009233816A JP2009233816A JP2010065037A5 JP 2010065037 A5 JP2010065037 A5 JP 2010065037A5 JP 2009233816 A JP2009233816 A JP 2009233816A JP 2009233816 A JP2009233816 A JP 2009233816A JP 2010065037 A5 JP2010065037 A5 JP 2010065037A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence
apo
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009233816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010065037A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010065037A publication Critical patent/JP2010065037A/ja
Publication of JP2010065037A5 publication Critical patent/JP2010065037A5/ja
Pending legal-status Critical Current

Links

JP2009233816A 2002-06-24 2009-10-07 Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法 Pending JP2010065037A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39105002P 2002-06-24 2002-06-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004516142A Division JP4574350B2 (ja) 2002-06-24 2003-06-23 Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法

Publications (2)

Publication Number Publication Date
JP2010065037A JP2010065037A (ja) 2010-03-25
JP2010065037A5 true JP2010065037A5 (lt) 2010-12-09

Family

ID=30000661

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004516142A Expired - Lifetime JP4574350B2 (ja) 2002-06-24 2003-06-23 Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法
JP2009233816A Pending JP2010065037A (ja) 2002-06-24 2009-10-07 Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004516142A Expired - Lifetime JP4574350B2 (ja) 2002-06-24 2003-06-23 Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法

Country Status (7)

Country Link
US (4) US20060141561A1 (lt)
EP (2) EP1556076A4 (lt)
JP (2) JP4574350B2 (lt)
AU (2) AU2003247609A1 (lt)
CA (1) CA2489348A1 (lt)
IL (1) IL165777A0 (lt)
WO (1) WO2004001009A2 (lt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186051A1 (en) * 2001-10-02 2004-09-23 Kelley Robert F Apo-2 ligand variants and uses thereof
GB0328261D0 (en) * 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
JP2007530588A (ja) 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド レセプターカップリング剤およびその治療用途
EP1791864A2 (en) * 2004-09-08 2007-06-06 Genentech, Inc. Methods of using death receptor ligands and cd20 antibodies
GB0524316D0 (en) * 2005-11-29 2006-01-04 Medical Res Council Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
KR100886783B1 (ko) * 2006-06-12 2009-03-04 성균관대학교산학협력단 N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도
WO2008088582A2 (en) * 2006-08-04 2008-07-24 Mayo Foundation For Medical Education And Research Methods and materials related to trail isoforms
EP2205282A2 (en) 2007-09-24 2010-07-14 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
RU2010121967A (ru) 2007-10-31 2011-12-10 Медиммун, Ллк (Us) Белковые каркасные структуры
WO2011079293A1 (en) * 2009-12-23 2011-06-30 Ambrx, Inc Tumor necrosis factor-related apoptosis inducing ligand polypeptides and their uses
WO2011130324A1 (en) 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
SI2771022T1 (sl) 2011-10-11 2020-12-31 Viela Bio, Inc. CD40L-specifična ogrodja pridobljena iz TN3 in postopki njihove uporabe
JP6219923B2 (ja) 2012-03-28 2017-10-25 アムジェン インコーポレイテッド Ｄｒ５受容体アゴニストの組み合わせ
CA2920666A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
KR20150133576A (ko) * 2014-05-20 2015-11-30 삼성전자주식회사 화학적 개질된 표적화 단백질 및 그의 이용
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
WO2017106627A1 (en) 2015-12-17 2017-06-22 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
US11084879B2 (en) 2016-04-07 2021-08-10 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
IT201900024622A1 (it) 2019-12-18 2021-06-18 Univ Degli Studi G Dannunzio Chieti Pescara Pegilazione innovativa del killer tnf-apoptosis induced ligand (killer-trail)

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
ATE76311T1 (de) 1986-08-19 1992-06-15 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen.
KR0154872B1 (ko) 1987-12-21 1998-10-15 로버트 에이. 아미테이지 발아하는 식물종자의 아크로박테리움 매개된 형질전환
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
DK0417563T3 (da) 1989-09-12 2000-11-06 Hoffmann La Roche TNF-bindende proteiner
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
WO1992003478A1 (en) 1990-08-17 1992-03-05 Genentech, Inc. Metal ion mediated receptor binding of polypeptide hormones
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1992017200A2 (en) 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
AU6048294A (en) 1992-11-25 1994-06-22 Amgen Boulder Inc. Modified insulin-like growth factors
CA2160154A1 (en) 1993-04-07 1994-10-13 George N. Cox Methods of using insulin-like growth factor binding proteins
JPH09504174A (ja) * 1993-10-29 1997-04-28 インサイト ファーマシューティカルズ，インク． プロテアーゼネキシン１変異体を含むキメラ蛋白
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
DE69635480T2 (de) 1995-06-29 2006-08-17 Immunex Corp., Thousand Oaks Apoptosis induzierendes cytokin
WO1997011178A1 (en) 1995-09-21 1997-03-27 Genentech, Inc. Human growth hormone variants
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
ATE302272T1 (de) 1996-10-25 2005-09-15 Human Genome Sciences Inc Neutrokin alpha
ES2144386T5 (es) 1996-12-23 2012-12-07 Immunex Corporation Ligando para el activador del receptor de NF-kappa b, el ligando es miembro de la superfamilia de TNF
DE69837806T3 (de) 1997-01-28 2012-01-05 Human Genome Sciences, Inc. "death-domain"-enthaltender rezeptor 4 (dr4), ein mitglied der tnf-rezeptor superfamilie, welcher an trail (apo-2l) bindet
WO1998035026A1 (en) 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
CN1624128A (zh) 1997-03-17 2005-06-08 人类基因组科学公司 包含死亡结构域的受体－5
EP1007562A4 (en) 1997-04-16 2000-09-27 Millennium Pharm Inc TANGO-63d AND TANGO-63e PROTEINS RELATED TO THE TUMOR NECROSIS FACTOR RECEPTOR
SI0975754T2 (sl) 1997-04-16 2016-04-29 Amgen Inc., Vezivni proteini in receptorji osteoprotegerina
PT1860187E (pt) 1997-05-15 2011-10-04 Genentech Inc Receptor apo-2
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
CA2296770A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
EP1003864A1 (en) 1997-08-15 2000-05-31 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
DK1009817T3 (da) 1997-08-26 2010-01-18 Genentech Inc RTD-receptor
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
JP2002508962A (ja) * 1998-01-15 2002-03-26 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド
CA2318405C (en) 1998-01-26 2014-01-07 Genentech, Inc. Antibodies to death receptor 4(dr4) and uses thereof
ZA200002867B (en) 1999-06-09 2001-12-07 Pfizer Prod Inc Process for preparing sertraline from chiral tetralone.
US6318934B1 (en) * 1999-06-24 2001-11-20 Anchor Wall Systems, Inc. Segmental retaining wall system
WO2001000832A1 (en) 1999-06-28 2001-01-04 Genentech, Inc. Methods for making apo-2 ligand using divalent metal ions
ATE415978T1 (de) 2000-07-27 2008-12-15 Genentech Inc Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
US20040186051A1 (en) * 2001-10-02 2004-09-23 Kelley Robert F Apo-2 ligand variants and uses thereof

Similar Documents

Publication Publication Date Title
JP2010065037A5 (lt)
JP2010227108A5 (lt)
JP2010088434A5 (lt)
JP2011136981A5 (lt)
JP2009268467A5 (lt)
JP2013510581A5 (lt)
JP2010532978A5 (lt)
JP2011520976A5 (lt)
JP2011511933A5 (lt)
JP2016104015A5 (lt)
JP2012126742A5 (lt)
JP2010519252A5 (lt)
JP2007510403A5 (lt)
JP2007175057A5 (lt)
JP2014224126A5 (lt)
RU2018137842A (ru) Агонисты рецепторов глюкагона/glp-1 для лечения ожирения
JP2007508034A5 (lt)
JP2006006329A5 (lt)
JP2016527891A5 (lt)
JP2009542225A5 (lt)
JP2012505657A5 (lt)
JP2015038108A5 (lt)
JP2014525439A5 (lt)
JP2015119721A5 (lt)
WO2008113536A8 (en) Neurotrophic peptides